Compare Amgen, Inc. (AMGN) vs Visa Inc (V) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Visa Inc — how do they compare? Amgen, Inc. trades at $362.12 (market cap $196.12B), while Visa Inc trades at $349.96 (market cap $663.65B). The key difference: Visa Inc is far larger — about 3.4× Amgen, Inc.'s market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | V | |
|---|---|---|
Market Cap | $196.12B | $663.65B |
Sector | Health | Financials |
52-Week High | $388.16 | $362.13 |
52-Week Low | $271.18 | $295.52 |
Enterprise Value | $241.41B | $674.24B |
Dividend Yield | 2.77% | 0.77% |
Volume | — | 10,431,336 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Visa (V) trades at $348.97, up 0.22% on the day, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings expectations, with Q1 2026 EPS of $3.31 surpassing the $3.10 estimate. Revenue grew to $40 billion in 2025, and net income margin stands at 51.68%. Recent news highlights Visa's push into AI-driven commerce with Intelligent Commerce Connect, aiming to enhance transaction efficiency.
The outlook is positive, supported by a consensus price target of $395 and 85% analyst buy ratings. Risks include competitive threats from fintech and stablecoins, as noted by Stanley Druckenmiller (The Motley Fool, 2026-04-10). Upside potential exists from continued earnings growth and AI integration, but investors should monitor regulatory pressures and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Visa Inc
Visa Inc. operates a retail electronic payments network and manages global financial services. The Company also offers global commerce through the transfer of value and information among financial institutions, merchants, consumers, businesses, and government entities.
Read more on V →
